ClinConnect ClinConnect Logo
Search / Trial NCT06645535

The Gut Microbiota and Metabolites in HFpEF

Launched by THE FIRST AFFILIATED HOSPITAL WITH NANJING MEDICAL UNIVERSITY · Oct 15, 2024

Trial Information

Current as of July 09, 2025

Enrolling by invitation

Keywords

Gut Microbiota Metabolites H Fp Ef

ClinConnect Summary

1. Heart failure with preserved ejection fraction is an urgent clinical challenge As the leading killer of human life and health, cardiovascular disease is a difficult public health problem worldwide. According to the latest statistics of China Cardiovascular Health and Disease Report 2022, the number of patients in China has exceeded 330 million, and the number of patients with heart failure (HF) is as high as 8.9 million, becoming the second leading cause of death related to heart disease after coronary heart disease. According to the 2023 European Society of Cardiology (ESC) guidelines f...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 1. Male or female, ≥18 years old;
  • 2. With symptoms and signs of chronic heart failure, NYHA class II-IV;
  • 3. LVEF≥50% according to the most recent echocardiography before screening, and no previous record of LVEF\<50%;
  • 4. BNP \>35 pg/mL, or NT-proBNP \>125 pg/mL;
  • 5. Comply with at least one of the following:
  • (1) LVMI ≥ 115g/m2 (men) 95g/m2 (women); (2) RWT \> 0.42; R (3) E/e '\>15; (4) septal e '\<7cm/s or lateral e' \<10cm/s or mean e '\<8cm/s; (5) TVR\>2.8m/s or PASP\>35mmHg.
  • Exclusion Criteria:
  • Patients with confirmed chronic or acute renal insufficiency (stage II-IV)

About The First Affiliated Hospital With Nanjing Medical University

The First Affiliated Hospital of Nanjing Medical University is a leading medical institution dedicated to advancing healthcare through innovative research and clinical excellence. As a prominent sponsor of clinical trials, the hospital is committed to implementing rigorous scientific methodologies to evaluate new therapies and treatment approaches. With a multidisciplinary team of experienced healthcare professionals and researchers, the hospital fosters a collaborative environment aimed at enhancing patient outcomes and contributing to the global medical community. Its strategic focus on translational medicine ensures that groundbreaking discoveries are efficiently translated into practical applications for patient care.

Locations

Naning, Jiangsu, China

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported